This review discusses glutamatergic modulators in treating major depression, focusing on NMDA-targeted therapies like ketamine and esketamine.

This study reveals that individuals with depression exhibit an expanded frontostriatal salience network. The expansion is stable over time and may serve as a trait-like marker for depression risk.